Skip to main content

Table 3 Twelve-month demographic and clinical data of rheumatoid arthritis patients in different remission statuses

From: Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder

 

DAS28 remission (n = 102)

Only DAS28 remission (n = 75)

DAS28 + Boolean remission (n = 27)

Not in any remission (n = 171)

DAS28(4v)-CRP

1.99 ± 0.31

2.08 ± 0.28

1.75 ± 0.27

3.97 ± 1.12

TJC28

0.17 ± 0.45

0.17 ± 0.48

0.15 ± 0.36

4.92 ± 5.39

SJC28

0.41 ± 1.17

0.53 ± 1.34

0.07 ± 0.27

4.05 ± 4.66

CRP (mg/dl)

0.53 ± 0.61

0.56 ± 0.71

0.43 ± 0.14

1.28 ± 2.84

PGH

2.08 ± 1.56

2.58 ± 1.52

0.7 ± 0.46

4.99 ± 2.39

Low disease activity (%)

100

100

100

28.1

Responder (%)

100

100

100

71.9

Good response (%)

94.1

92

100

24.6

Moderate response (%)

5.9

8

0

47.4

Nonresponse (%)

0

0

0

28.1

  1. Data presented as mean ± standard deviation or percentage. DAS28, disease activity score based on 28-joint count; DAS28(4v)-CRP, disease activity score based on 28-joint count, C-reactive protein and patient global health; TJC28, tender joint count out of 28 joints; SJC28, swollen joint count out of 28 joints; CRP, C-reactive protein; PGH, patient global health.